Karolina MAREK-BUKOWIEC

Dr. Karolina MAREK-BUKOWIEC

Regional Specialist Hospital, Wrocław, Dolnośląskie, Poland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JMJoanna Majewska
Joanna Majewska
ZKZuzanna Kaźmierczak
Zuzanna Kaźmierczak
KLKarolina Lahutta
Karolina Lahutta
DLDorota Lecion
Dorota Lecion
ASAleksander Szymczak
Aleksander Szymczak
KDKrystyna Dąbrowska
Krystyna Dąbrowska
In therapeutic phage applications oral administration is a common and well-accepted delivery route. Phages applied per os may elicit a specific humoral response, which may in turn affect phage activity. We present specific anti-phage antibody induction in mice receiving therapeutic staphylococcal bacteriophage A3R or 676Z in drinking water. The schedule comprised: (1) primary exposure to phages for 100 days, followed by (2) diet without phage for 120 days, and (3) secondary exposure to the same phage for 44 days. Both phages induced specific antibodies in blood (IgM, IgG, IgA), even though poor to ineffective translocation of the phages to blood was observed. IgM reached a maximum on day 22, IgG increased from day 22 until the end of the experiment. Specific IgA in the blood and in the gut were induced simultaneously within about 2 months; the IgA level gradually decreased when phage was removed from the diet. Importantly, phage-specific IgA was the limiting factor for phage activity in the gastrointestinal tract. Multicopy proteins (major capsid protein and tail morphogenetic protein H) contributed significantly to phage immunogenicity (IgG), while the baseplate protein gpORF096 did not induce a significant response. Microbiome composition assessment by next-generation sequencing (NGS) revealed that no important changes correlated with phage treatment.

15 November 2018 in Viruses
Verified
Journal Article
Open access
PDF file
MHMarek Harhala
Marek Harhala
DNDaniel C. Nelson
Daniel C. Nelson
PMPaulina Miernikiewicz
Paulina Miernikiewicz
RHRyan Heselpoth
Ryan Heselpoth
BBBeata Brzezicka
Beata Brzezicka
KDKrystyna Dąbrowska
Krystyna Dąbrowska
Bacteriophage-derived endolysins have gained increasing attention as potent antimicrobial agents and numerous publications document the in vivo efficacy of these enzymes in various rodent models. However, little has been documented about their safety and toxicity profiles. Here, we present preclinical safety and toxicity data for two pneumococcal endolysins, Pal and Cpl-1. Microarray, and gene profiling was performed on human macrophages and pharyngeal cells exposed to 0.5 µM of each endolysin for six hours and no change in gene expression was noted. Likewise, in mice injected with 15 mg/kg of each endolysin, no physical or behavioral changes were noted, pro-inflammatory cytokine levels remained constant, and there were no significant changes in the fecal microbiome. Neither endolysin caused complement activation via the classic pathway, the alternative pathway, or the mannose-binding lectin pathway. In cellular response assays, IgG levels in mice exposed to Pal or Cpl-1 gradually increased for the first 30 days post exposure, but IgE levels never rose above baseline, suggesting that hypersensitivity or allergic reaction is unlikely. Collectively, the safety and toxicity profiles of Pal and Cpl-1 support further preclinical studies.

KRKrzysztof Ratajczyk
Krzysztof Ratajczyk
AKAndrzej Konieczny
Andrzej Konieczny
ACAdrian Czekaj
Adrian Czekaj
PPPaweł Piotrów
Paweł Piotrów
MFMarek Fiutowski
Marek Fiutowski
KMKarolina MAREK-BUKOWIEC
Karolina MAREK-BUKOWIEC
Effective biomarkers for early diagnosis, prognostication, and monitoring in renal diseases (in general) comprise an unmet need. Urinary retinol-binding protein 4, which is the most sensitive indicator of renal tubular damage, holds great promise as a universal biomarker for renal pathologies, in which tubular injury is the driving force. Here, we summarize the most important existing data on the associations between urinary retinol-binding protein 4 and renal diseases and highlight the untapped potential of retinol-binding protein 4 in clinical use.

1 February 2019 in Analytica Chimica Acta
Verified
Journal Article
Closed access
MWMateusz Waliczek
Mateusz Waliczek
RBRemigiusz Bąchor
Remigiusz Bąchor
MKMonika Kijewska
Monika Kijewska
DGDorota Gąszczyk
Dorota Gąszczyk
KPKarolina Panek-Laszczyńska
Karolina Panek-Laszczyńska
PPiotr Stefanowicz
Piotr Stefanowicz

21 May 2021 in Polish Archives of Internal Medicine
Verified
Journal Article
Closed access
KMKarolina MAREK-BUKOWIEC
Karolina MAREK-BUKOWIEC
AKAndrzej Konieczny
Andrzej Konieczny
KRKrzysztof Ratajczyk
Krzysztof Ratajczyk
HCHanna Czapor-Irzabek
Hanna Czapor-Irzabek
AGAgata Górniak
Agata Górniak
PKPaweł Kowal
Paweł Kowal
DOI: 10.20452/pamw.16005, Published online: May 21, 2021, Authors: Karolina Marek-Bukowiec, Andrzej Konieczny, Krzysztof Ratajczyk, Hanna Czapor-Irzabek, Agata Górniak, Paweł Kowal

1 March 2013 in Journal of Immunological Methods
Verified
Journal Article
Closed access
MKMikołaj Kłossowicz
Mikołaj Kłossowicz
BŚBożena Ścirka
Bożena Ścirka
JSJoanna Suchanek
Joanna Suchanek
KMKarolina MAREK-BUKOWIEC
Karolina MAREK-BUKOWIEC
PKPawel Kisielow
Pawel Kisielow
AMArkadiusz Miazek
Arkadiusz Miazek